Melphalan: profile and news

Velcade® plus Melphalan Shows Encouraging Activity in Multiple ...  Feb 23, 2006
...recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Velcade® (bortezomib) and melphalan (Alkeran®) provides ... - Cancer Consultants (press release),

Delcath Systems Announces Initial Patient Treatment In Phase III ...  Mar 1, 2006
System in its pivotal Phase III clinical trial for the treatment of metastatic melanoma in the liver using the Delcath system with melphalan, an approved ... - PharmaLive.com (press release),

Delcath Systems Receives Special Protocol Assessment and Agreement ...  Feb 22, 2006
SPA) with the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma in the liver using the Delcath system with melphalan, an approved ... - International News Service,

Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ...  Feb 28, 2006
...transplantation. This is because this is a less marrow-toxic regimen than the more conventional Alkeran®-(melphalan) based regimens. ... - Cancer Consultants (press release),

Delcath Systems initiates phase III trial in melanoma  Mar 2, 2006
...the body from excessive toxicity. The system will be tested with melphalan, an approved anticancer agent. The company says that ... - Pharmaceutical Business Review

Delcath Systems receives FDA OK for cancer trial  Feb 22, 2006
SPA) with the US Food and Drug Administration for the treatment of metastatic melanoma in the liver using the Delcath system with melphalan, an approved ... - Boston Mass High Tech,

Delcath Systems Receives NCI Institutional Review Board Approval  Feb 7, 2006
Board (IRB) has approved the Company's pivotal Phase III clinical trial for the treatment of metastatic melanoma in the liver with melphalan, an approved ... - PR Newswire (press release),

Gentium to Present at Angiogenesis in Cancer and Vascular Disease ...  Feb 2, 2006
Defibrotide is the subject of an independent Phase I/II study to treat Multiple Myeloma (MM) in combination with Melphalan, Prednisone, and Thalidomide (MPT ... - Genetic Engineering News,

Treanda™/Prednisone Superior to Melphalan/Prednisone for ...  Jan 30, 2006
...the steroid prednisone appears to provide superior outcomes to a standard treatment regimen consisting of the chemotherapy agent melphalan (Alkeran®) plus ... - Cancer Consultants (press release),

Treanda TM (Bendamustine) Plus Prednisone Superior to Melphalan ...  Jan 27, 2006
...the complete remission rate, prolongs time to treatment failure and improves quality of life compared to standard oral Alkeran® (melphalan) and prednisone ... - Cancer Consultants (press release),

Delcath Systems Receives NCI Institutional Review Board Approval  Feb 7, 2006
Board (IRB) has approved the Company's pivotal Phase III clinical trial for the treatment of metastatic melanoma in the liver with melphalan, an approved ... - PR Newswire (press release),

Celgene Corporation Reports Record Operating Performance for 2005  Jan 26, 2006
...significant difference in event-free survival of 68 percent versus 32 percent (p<0.001) after twenty-six months of treatment with melphalan, prednisone and ... - PR Newswire (press release),

Gentium to Present at Angiogenesis in Cancer and Vascular Disease ...  Feb 2, 2006
Defibrotide is the subject of an independent Phase I/II study to treat Multiple Myeloma (MM) in combination with Melphalan, Prednisone, and Thalidomide (MPT ... - Genetic Engineering News,

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
VELCADE in combination with melphalan and prednisone in the multiple myeloma front-line treatment setting showed response rates comparable to those typically ... - Biotech Intelligence (press release),

Delcath Systems Co-Sponsors First International Symposium On ...  Jan 24, 2006
...through 2004, and their ongoing experience in the Phase II trial for the treatment of primary and metastatic tumors in the liver using melphalan, an approved ... - PR Newswire (press release),

Delcath Systems to Present at Brean Murray, Carret & Co. Small Cap ...  Jan 26, 2006
In May 2005, Delcath received fast-track status from the US FDA for the treatment of metastatic melanoma in the liver with melphalan using the Delcath system. ... - PR Newswire (press release),

Natco Pharma launches blood cancer drug  Dec 8, 2005
Natco Pharma Ltd. on Thursday announced the launch of its brand, Alphalan (Melphalan) in 2 mg and 5 mg tablet forms. The launch ... - India Infoline.com,

Delcath Receives Additional US Patent for Cancer Treatment System  Dec 8, 2005
...we continue our current trials and move toward beginning our fast-track Phase III clinical trials for the treatment of liver cancer using melphalan," Koly added ... - Yahoo! News (press release)

Delcath dealt another patent for chemotherapy delivery system  Dec 8, 2005
Delcath received fast-track status from the US Food and Drug Administration for the treatment of metastatic melanoma in the liver with melphalan, an approved ... - Boston Mass High Tech,

New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ...  Dec 6, 2005
...of peripheral neuropathy (abstract #3336) * Single-agent or combination therapy in the front-line setting -- Combination with melphalan and prednisone ... - PR Newswire (press release),

Delcath Systems Announces Listing of Warrants  Dec 1, 2005
In May 2005, Delcath received fast-track status from the US FDA for the treatment of metastatic melanoma in the liver with melphalan, an approved anticancer ... - Yahoo! News (press release)

Delcath Receives Canadian Patent for Novel Apparatus and Method ...  Nov 21, 2005
...liver cancer." In May of 2005, Delcath received fast-track status from the US FDA for treating metastatic melanoma in the liver with melphalan, a currently ... - PR Newswire (press release),

Melphalan/Prednisone Favorable in Multiple Myeloma Patients ...  Sep 30, 2005
...to a recent article published ahead of print in the journal Blood, the treatment combination consisting of the chemotherapy agent melphalan (Alkeran®) plus ... - Cancer Consultants (press release),

Alkeran®/Prednisone Remains Standard Therapy for Elderly Patients ...  Oct 4, 2005
Researchers affiliated with the Intergroupe Francophone du Myelome (IFM) have concluded that a regimen of Alkeran® (melphalan) and prednisone is preferred to ... - Cancer Consultants (press release),

Zevalin® May Substitute for Total Body Irradiation When Combined ...  Oct 6, 2005
...of Zevalin can be administered in combination with the common transplant regimen of BEAM (carmustine, etoposide, cytarabine and melphalan) with autologous stem ... - Cancer Consultants (press release),

Committee for Medicinal Products for Human Use Post-authorisation ...  Sep 16, 2005
The new indication adopted by CHMP is: “Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to ... - PharmaLive.com (press release),

Ethyol® Allows Greater Tolerability of Chemotherapy in Head and ...  Sep 29, 2005
...in patients receiving pelvic radiation therapy and more recently has been associated with decreased toxicities in patients receiving high-dose melphalan. ... - Cancer Consultants (press release),

*vwd/BUSINESS WIRE: Gentium SpA gibt Beginn der unabhängigen ...  Sep 21, 2005
Krebszentren in Italien im Bezug auf die Behandlung von Patienten mit Multiplem Myelom (MM) in Kombination mit der Anwendung von "Melphalan", "Prednisone" und ... - Vereinigte Wirtschaftsdienste,

High-Dose Sequential Chemotherapy and Autologous Stem Cell ...  Sep 13, 2005
The transplant regimen was BEAM (cytarabine, etoposide, melphalan and carmustine). At the end of this therapy the complete response rate was 43%. ... - Cancer Consultants (press release),

Gentium SpA Announces Initiation of Independent Phase I/II Study ...  Sep 21, 2005
...lead product, Defibrotide, will be the subject of an independent Phase I/II study to treat Multiple Myeloma (MM) in combination with Melphalan, Prednisone, and ... - Business Wire (press release),

High-Dose Sequential Chemotherapy and Autologous Stem Cell ...  08 Sep 2005
The transplant regimen was BEAM (cytarabine, etoposide, melphalan and carmustine). At the end of this therapy the complete response rate was 43%. ... - Cancer Consultants (press release),

Mayo Clinic Research Shows Promise For Myeloma Patients Using A ...  Sep 2, 2005
Standard therapy of melphalan and prednisone results in about 50 percent of patients having a positive response -- ie the cancer cells lessen by more than half ... - Science Daily (press release)

Multiple myeloma, Revlimid and Dexamethasone show promise  Sep 3, 2005
Standard therapy of Melphalan and Prednisone results in about 50 percent of patients having a positive response – ie the cancer cells lessen by more than half ... - Xagena.it,

Chemotherapy and Autologous Stem Cell Transplant Improve Outcome ...  Aug 23, 2005
After initial chemotherapy and surgery, half of the children received high-dose chemotherapy (melphalan, etoposide, and carboplatin) and autologous stem-cell ... - Cancer Consultants (press release),

Efficacy of High-Dose Chemotherapy with Autologous Stem Cell ...  Aug 19, 2005
More recently, researchers in England performed a randomized trial evaluating high-dose Alkeran® (melphalan) in children with advanced neuroblastoma who ... - Cancer Consultants (press release),

Combination chemotherapy with gemcitabine with isolated lung ...  Jul 12, 2005
We studied the in vivo and in vitro efficacy of combinations of gemcitabine, cisplatin, and melphalan. METHODS: In vitro, using ... - The Journal of Thoracic and Cardiovascular Surgery

Correlation Between Serum Levels of Free Light Chain and Phenotype ...  Jul 14, 2005
Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-3670. 13. ... - RedNova.com <**results**>

Delcath Reports on 2005 Annual Meeting  Jun 15, 2005
The NCI has subsequently begun treatment of patients in a Phase II study, infusing high doses of melphalan through the Delcath system. ... - PrimeZone (press release)

Two Studies Show Zevalin® Effective in Elderly Patients with ...  Jun 30, 2005
States have reported that Zevalin (Yttrium 90 ibritumomab tiuxetan) alone or combined with high-dose carmustine, etoposide, cytarabine and melphalan (BEAM) is ... - Cancer Consultants (press release)

Two New Studies in the British Journal of Haematology Show ...  Jun 8, 2005
High-dose melphalan was administered, peripheral blood stem cells were infused, and the rate of hematologic recovery was assessed. ... - Yahoo News (press release)

Combined Use of ^Sup 99m^Tc-Sestamibi and ^Sup 99m^Tc-V-DMSA in ...  Jun 15, 2005
...an oral agent, was also often used as salvage therapy for myeloma patients, alone or in combination with dexamethasone or melphalan and dexamethasone. ... - RedNova.com,